Maximal Androgen Blockade for Metastatic Prostate Cancer
Author Information
Author(s): H. Lukka, T. Waldron, L. Klotz, E. Winquist, J. Trachtenberg
Primary Institution: Cancer Care Ontario Program in Evidence-based Care
Hypothesis
Is maximal androgen blockade associated with a survival advantage compared to castration alone in metastatic prostate cancer?
Conclusion
Maximal androgen blockade offers a small survival benefit but comes with significant toxicity and reduced quality of life, making it not routinely recommended.
Supporting Evidence
- Maximal androgen blockade showed a statistically significant improvement in 5-year survival over castration alone (27.6% vs. 24.7%).
- Using cyproterone acetate with maximal androgen blockade was associated with a significantly increased risk of death (15.4% vs. 18.1%).
- Patients treated with maximal androgen blockade experienced more side effects and a decline in quality of life.
Takeaway
Doctors looked at different treatments for prostate cancer and found that using two medicines together helps a little but can also make patients feel worse.
Methodology
A systematic review of meta-analyses comparing maximal androgen blockade with castration alone in untreated men with metastatic prostate cancer.
Potential Biases
Potential publication bias may exaggerate treatment effects due to reliance on published data.
Limitations
The review is limited by the variability in trial quality and the focus on overall survival without assessing other important outcomes like quality of life.
Participant Demographics
The study included previously untreated men with metastatic prostate cancer.
Statistical Information
P-Value
0.005
Confidence Interval
95% CI: 0.91–1.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website